Efficacy and Safety of Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization for Hepatocellular Carcinomas Compared with Radiofrequency Ablation Alone: A Time-to-Event Meta-Analysis.
- Author:
Xin WANG
1
;
Yanan HU
;
Mudan REN
;
Xinlan LU
;
Guifang LU
;
Shuixiang HE
Author Information
- Publication Type:Original Article ; Comparative Study ; Meta-Analysis
- Keywords: Transcatheter arterial chemoembolization; Radiofrequency ablation; Hepatocellular carcinomas; Meta-analysis
- MeSH: Carcinoma, Hepatocellular/*surgery; Catheter Ablation/adverse effects/*methods; Chemoembolization, Therapeutic/adverse effects/*methods; China; Combined Modality Therapy; Disease-Free Survival; Humans; Liver Neoplasms/*surgery; Odds Ratio; Proportional Hazards Models; Treatment Outcome
- From:Korean Journal of Radiology 2016;17(1):93-102
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVE: To compare the efficacy and safety of combined radiofrequency ablation (RFA) and transcatheter arterial chemoembolization (TACE) with RFA alone for hepatocellular carcinomas (HCC). MATERIALS AND METHODS: Randomized controlled trial (RCT) studies that compared the clinical or oncologic outcomes of combination therapy of TACE and RFA versus RFA for the treatment of HCC were identified through literature searches of electronic databases (Pubmed, Embase, Cochrane Library, China Biology Medicine disc, China National Knowledge Infrastructure, and Google Scholar). Hazard ratios (HRs) or odds ratios (ORs) with their corresponding 95% confidence interval (CI) were combined as the effective value to assess the summary effects. The strength of evidence was rated by the Grading of Recommendations Assessment, Development, and Evaluation system. RESULTS: Six RCTs with 534 patients were eligible for inclusion in this meta-analysis. The meta-analysis showed that the combination of TACE and RFA is associated with a significantly longer overall survival (HR = 0.62, 95% CI: 0.49-0.78, p < 0.001) and recurrence-free survival (HR = 0.55, 95% CI: 0.40-0.76, p < 0.001) in contrast with RFA monotherapy. The seemingly higher incidence of major complications in the combination group compared with RFA group did not reach statistical significance (OR = 1.17, 95% CI: 0.39-3.55, p = 0.78). CONCLUSION: In patients with HCC, the combination of TACE and RFA is associated with significantly higher overall survival and recurrence-free survival, as compared with RFA monotherapy, without significant difference in major complications.
